7
Participants
Start Date
July 10, 2015
Primary Completion Date
May 30, 2019
Study Completion Date
May 30, 2019
Dacomitinib
Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
Kanazawa University Hospital, Kanazawa
Kurashiki Central Hospital, Kurashiki
Osaka City General Hospital Department of Clinical Oncology, Osaka
Kindai University Hospital, Sayama
Shizuoka Cancer Center, Suntougun
Cancer Institute Hospital,Japanese Foundation for Cancer Research, Koto-Ku
Lead Sponsor
Pfizer
INDUSTRY